Letter to CSPI et al. from Dr. Peter Marks

FDA Warns Joseph Mercola Not to Market Products Making Fake Claims to Treat or Prevent COVID-19

Director of FDA's CBER Responds to CSPI Letter

Dr. Peter Marks, director of the Food and Drug Administration’s Center for Biologics Evaluation and Research, responded to a CSPI-organized letter from 400 prominent experts in vaccine technology, epidemiology, virology, and other public health fields urging that the FDA not make a COVID-19 vaccine widely available until Phase 3 clinical trials are complete.

View resource